The development of multiple p rimary pleomorphic adenomas in a single parotid gland is extremely rare in previously untreated patients, as only nine cases have been pr eviously reported. In this article, we report the tenth such case, which occurred in an 87-year-old Japanese woman. We also report the results of our 7-plus-year review of the types ofparotid tumors seen at our institution. We identified 98 tumors in 89 pati ents; pleomorphic adenomas were the most common tumors, accounting for 45.9 % of the total.
Introduction
The development of multiple separate tumors arising in a single salivary gland is rare in previously untreat ed patients . Most such masses are multifocal Warthin ' s tumor s (adenolymphomas). The most common tumors of the salivary glands are pleomorphic adenomas (mixed tumors) . Likewise, the incidence of multiple primary unilateral pleomorphic adenomas in previously untreated patients is extremely rare, as only nine cases have been previously reported. In this article, we report the tenth such case, and we review the literature on this condition. tenderne ss, discomfort, fever , facial nerve dysfunction, sensory disturbance, and xerostomia. She had no history of surgery, aspiration biopsy, or radiotherapy to the head or neck .
Our physical examination revealed the presence of a preauricular mass that was 24 x 22 mm in diameter and rather firm , smooth, and movable. Another mass was slightly palpable between the mastoid tip and the angle of the mandible. The patient's facial nerve function was completely normal.
Axial-plane computed tomography (CT) detected two round , discrete lesions in the left parotid gland. Intravenous contrast CT demonstrated a slight enhancement of the margin of the superio r, superficial mass and a rather homogenous enhancement of the inferior, deep mass.
Tl-weighted magnetic resonance imaging (MRI) showed a relatively homogenous, low signal intensity in both masses , while T2-weighted MRI showed a very high signal intensity in the superficial mass and an isosignal intensity in the deep mass (figure 1). A technetium 99m pertechnetate salivary scan revealed a cold spot in the left parotid , while 67Ga scintigraphy showed a hot spot there . Ultra sound examination of the parotid showed that the superficial lesion was oval and the deep lesion had some lobe s. A tentativ e preoperative diagnosis of either multiple pleomorphic adenomas or a pleomorphic adenoma associated with a malignant lymphoma was made.
The patient underwent a left lateral superficial parotid lobectomy with facial nerve preservation. Intraoperative examination identified a smooth mass in the superior portion of the parotid gland anterior to the ear and another smooth mass between the mastoid tip and the angle of the mandible. The two masses were widely separate and discrete.
On gross pathology, the superficial and the deep nodules measured 17 x 13 mm and 18 x 10 mm, respectively. Check out the savings! Both were clearly well encapsulated and surrounded by normal salivary gland tissue , The cut section of the superior tumor was softer than that of the inferior mass, and it contained a small amount of brown fluid (figure 2), The inferior tumor had a white, lobulated, and firm surface , Microscopic analysis revealed that both tumors had a complete fibrous capsule and were separate from each other. The central space of the superior tumor contained prominent myxoid components. Several random small ducts and myoepithelial cells were darkly stained and spindle shaped (figure 3). The space near the capsule was made up primarily of ductal structures and myoepithelial cells. Similarly, the inferior tumor was made up primarily of ductal structures, and darkly stained, spindle-shaped myoepithelial cells surrounded the duct-lining cells (figure 4). Epithelial and myoepithelial cells formed the major part of the inferior tumor, and stromal components were difficult to find. No mitotic figures were observed .
The patient's postoperative course was uneventful, and her facial nerve functioned well. She was discharged on the eighth postoperative day. At follow-up 1 month later, the wound was well healed . Two years later, she has had no recurrence of either tumor.
Discussion
Several large studies have found that the pleomorphic 3 MULTIPLE PRIMARY PLEOMORPHIC ADENOMAS IN A SING LE PAROT ID GLAND : REPORT OF A NEW CASE adenoma, the most common tumor of the parotid gland , accounts for 55 to 65% of all parotid tumors.P It is also the most common tumor of all the salivary glands.
During the 7-plus years from June 1992 to November 1999, 89 patie nts with 98 parotid gland tumors were treated at our institution, the Himeji National Hospital in Japan (table I) . Of the 98 tumors, 91 were benign (92.9%), including 45 pleomorphic adenomas (45.9%). By contrast, Bardwif found that pleomorphic adenomas accounted for only 24.0% of all parotid gland tumors, while Eneroth" reported a much higher figure of 70.9 %.
Nine of the 89 patients at our institution had two distinct parotid tumors each (table 2). The development of multiple separate tumors in the salivary glands is rare in previously untreated patients. In many cases, these multiple masses were identified as Warthin ' s tumors . Accordin g to currently accepted theory, Warthin ' s tumor s origin ate in salivary duct epithelium and acini that are enclo sed by lymph nodes inside and outside the parotid gland .' Multiple Warthin ' s tumor s are believed to arise when multiple lymphoid tissues become involved with these duct al epithelial elements.
In a study of 278 cases ofWarthin' s tumor, Eveson and Cawson found that 13 (4.7%) were bilater al. 6 Foote and Frazell found bilateral tumors in six of 44 patients (13.6%). 7 Warthin's tumor is also the most likely lesion to manife st multifocal unilateral involvement. Gnepp et al reviewed the records of 25 patients who had synchronous unilater al salivary gland tumors.8 The y found coexisting benign and malignant tumors in six patients (24.0%) and coexi sting benign tumor s (e.g., Warthin ' s tumors, pleom orph ic adenom as, and oncocytom as) in 17 patients (68.0 %). In our review of 89 patients with 98 parotid masses, we found that nine patients had synchronous tumo rs. Seven of these patient s had Warthin ' s tumors-six unilater ally and one bilaterally.
Multiple pleomorphic adenomas of the major saliva ry glands are belie ved to arise under three circum stance s: (1) as a recurrence after an incomplete excision of a tumor, (2) as a result of implantation during aspirat ion biops y, and (3) as separate primary tumors:
Recurrence. Most cases of multiple pleomorphic adenomas are con side red to be recurrences.' The mult iple lesions arise as a result of the dissemination of residual fragments of tissue during surgery on the primary tumor." Pleomorphic adenomas are well circumscribed and typically characterized by a smooth, fibrous, pseudocapsule that varies in thickne ss and compl eteness. Thi s variance in structure is the reason the capsule is often penetrated by tumor tissue and destro yed. The high rate of recurrence of pleomorphic adenomas has been attributed to their infilt rative and destructive growth.'? Batsaki s sugges ted that recu rren ce is also a con sequence of rupture, seeding, or inadequate remov al. 5 The two most likely reaso ns for recurrence are the poor structural character of a lesion and an incomplete excision. However, a change in surgic al strategy from local excision to superficial or total parotidect omy has resulted in a decre ase in the recurrence rate from 8 to 2%.11 Recurrence can also be prevented by meticulous intraoperative inspection and palp ation of the glandular tissue. At our facility , there were no recurrences among the 45 patients with pleomo rphic adenomas who were available for follow-up, which rang ed from 2 to 10 years. Implantation. Tumor implantation during an aspiration biopsy is an important issue."Eneroth described three cases of multipl e unilateral pleomorphic adenomas of the parotid gland at sites where there had been a previou s needle aspiration of the parotid. "
Primary tumor. The occurrenc e of multiple pleomorphic adenom as as primary tumors is extremely rare. Only nine cases have been pre viously report ed. In 1953, Foote and Frazell described two cases; one patient had two pleomo rphic adenomas in the same parotid gland , and the other had two pleomorphic adenomas in the right parotid and one in the left.' In 1954, Andre described a patient who had two pleomorphi c adenomas in the right parotid." Turnbull and Frazell described three cases in 1969.'3 In 1982, Behnke reported the case of a patient who had two pleomorphi c adenom as in the right parotid." Batsakis" described one case in 1986, and Fran zen and Koegel"
The following treatment -related adverse events were each repo rted in a single subject: dermatitis, eczema , erythema tous rash, follicular rash, rash, hypoaest hesia , tinnitus , dyspepsia , hot flus hes, flushing, and otorrhagia.
Subjects withOtitisExterna
The following treatment-related adverse events occurred in 1% or more of the subjects with intact tympanic membranes.
Subjects with Acute Otitis Media with Tympanostomy Tubes and Subjects with Chronic SuppurativeOtitisMedia with Perforated Tympanic Membranes
The following treatment-related adverse events occurred in 1% or more of the subjects with non-intact tympanic memb ranes . Nursing Mother s : In nursing women , a single 200 mg oral dose resulted in concentrations of ofloxacin in milk which were similar to those found in plasma. It is not known whether ofloxacin is excreted in human milk following topical otic administration. Because of the potential for seriaus adversereactions from ofloxacin in nursing infants, a decision should be madewhether to discontin ue nursing or to discontin ue the drug, taking into account the importance of the drug to the mother. Pedi atric Use: No changes in hearing function occurred in 30 pediatric subjects treated with ofloxacin otic and tested for audiomet ric parameters . Although safety and efficacy have bee n demonst rated in pediatric patients one year and older, safety and effectiveness in infants below the age of one year have not been established . Although quina lones, including ofloxacin, have been shown to cause arthropathy in immature animals after systemic administration, young growing guinea pigs dosed in the middle ear with 0.3% ofloxacin otic solution for one month showed no systemic effects, quinolone-induced lesions, erosio ns of the cartilage in weightbearing joints, or other signs of arthropathy. ADVERS E REACTIONS In the Phase III registration trials, a total of 885 subjects were treated with ofloxacin otic solution. This included 229 subjects with otitis externa (with intact tympanic membranes) and 656 subjects with acute otitis media with tympanostomy tubes or chronic suppurative otitis media with perforated tympanic membranes. The reported treatment -related adverse events are listed below:
4%
References: The systemic administration of quinolones, including ofloxacin at doses much higher than given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bearing joints and othe r sig ns of arthropathy in immature animals of var ious spec ies. Young growing guinea pigs dosed in the middle ear with 0.3% ofloxacin otic solution showed no systemic effects, lesions or erosions of the cartilage in weight-bea ring joints, or other signs of arthropathy. No drug-re lated structu ral or functional changes of the cochlea and no lesions in the ossicles were noted in the guinea pig following otic administration of 0.3% ofloxacin for one month.
No signs of local irritation were found when 0.3% ofloxacin was applied topically in the rabbit eye. Ofloxacin was also shown to lack dermal sensiti zing potent ial in the guinea pig maximiza tion study. Information for Patient s : Avoid contaminating the applicator tip with material from the fingers or other sources. This precaution is necessary if the sterility of the drops is to be preserved . Systemic quinolones, including ofloxacin, have been associated with hypersensitivity reactions , even following a single dose . Discontinue use immediate ly and contact your physicia n at the first sign of a rash or allergic reaction. Otitis Extern a Prior to admin istration of FLOXIN@Otic in patients with otitis externa , the solution should be warmed by holding the bottie in the hand for one or two minutes to avoid dizziness which may result from the instillation of a cold solution.The patient should lie with the affected ear upward , and then the drops should be instilled. This position sho uld be maintained for five minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessa ry, for the opposite ear (see DOSAGE AND ADMINISTRATION). Acute Otitis Medi a and Chronic Suppurative Otitis Medi a In pedia tric patients (from 1 to 12 years old) with acute otitis media with tympanostomy tubes and in patients with chronic suppurative otitis media with perforated tympanic membranes, prior to administration , the solution shou ld be warmed by holding the bottie in the hand for one or two minutes to avoid dizziness which may result from the instillation of a cold solution. The patie nt should lie with the affected ear upward, and then the drops should be instilled.The tragus should then be pumped 4 times by pushing inward to facilitate penetration of the drops into the midd le ear. This pos ition shou ld be maintained for five min utes. Repea t, if necessary, for fhe opposite ear (see DOSAGE AND ADMINISTRATfON). Drug Interactions : Spec ific drug interaction studies have not been conducted with FLOXIN@ Otic. Carcinogen es is , Mutagenesis, Imp airment of Fertility Long-term studies to determi ne the carcinoge nic potential of ofloxacin have not bee n conducted . Ofloxacin was not mutage nic in the Ames test, the sister chromatid exchange assay (Chinese hamster and huma n cell lines), the unscheduled DNA synthes is (UDS) assay using huma n fibroblasts , the domin ant lethal assay, or the mouse micro -nucleus assay. Ofloxacin was positive in the rat hepatocyte UDS assay, and in the mouse lymphoma assay. In rats, ofloxacin did not affect male or female reproduct ive perfo rmance at oral doses up to 360 mg/kg/day. This would be over 1000 times the maxi mum recommended clinical dose , based upon body surface area, assuming iotal absorptio n of ofloxacin from the ear of a patient treated wit h FLOXIN@ Ot ic tw ice pe r day. Pregnancy Teratogenic effects: Pregnancy Category C. Ofloxaci n has bee n shown to have an embryocidal effect in rats at a dose of 810 mg/kg/day and in rabbits at 160 mg/kg/day. These dosages resulted in decreased fetal body weights and increased fetal mortality in rats and rabbits, respectively. Minor fetal skeletal variations were reported in rats receiving doses of 810 mglkg/day. Ofloxacin has not been shown to be teratogenic at doses as high as 810 mg/kg/dayand 160 mglkg /day when administered to pregna nt rats and rabbits, respectively. Ofloxacin has not been shown to have any adverse effects on the developing embryo or fetus at doses relevant to the amount of ofloxacin that will be de livered ototopical ly at the recommended clinical doses . Nonteratogenic Eff ect s : Additio nal studies in the rat demonstrated that doses up to 360 mglkg /day during late gestation had no adverse effects on late fetal development , labor, delivery, lactation, neonatal viabi lity, or growth of the newborn. There are, however, no adequate and well-co ntrolled studies in pregnant women . FLOXIN@ Otic should be used during pregnancy only if the potent ial be nefit justifies the pote ntial risk to the fetus. We report the tenth such case, which was marked by the coexistence of two pleomorphic adenomas in the superficial lobe of the left parotid. We believe that the coexistence of the two tumors was the product of mere coincidence rather than the result of an association between the two. 
